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Abstract
The burden of HIV/AIDS and other transmissible diseases is higher in prison and jail settings than 
in the non-incarcerated communities that surround them. In this comprehensive review, we discuss 
available literature on the topic of clinical management of people infected with HIV, hepatitis B 
and C viruses, and tuberculosis in incarcerated settings in addition to co-occurrence of one or 
more of these infections. Methods such as screening practices and provision of treatment during 
detainment periods are reviewed to identify the effect of community-based treatment when 
returning inmates into the general population. Where data are available, we describe differences in 
the provision of medical care in the prison and jail settings of low-income and middle-income 
countries compared with high-income countries. Structural barriers impede the optimal delivery of 
clinical care for prisoners, and substance use, mental illness, and infectious disease further 
complicate the delivery of care. For prison health care to reach the standards of community-based 
health care, political will and financial investment are required from governmental, medical, and 
humanitarian organisations worldwide. In this review, we highlight challenges, gaps in knowledge, 
and priorities for future research to improve health-care in institutions for prisoners.
Introduction
In 1990, Jonathan Mann, the then first director of WHO's Global Programme on AIDS, 
stated that if you wanted to find HIV in a country, introduce it, wait a few years, and 
subsequently look at the disadvantaged populations and you will find it there. Incarcerated 
populations are among the most disadvantaged in many societies. In nearly all See Online 
for appendix countries, the burden of HIV and AIDS and many other transmissible diseases 
is higher in prisons, jails, and other types of detention centres—which will collectively be 
referred to here as prisons—than in the communities that surround them.1 Partly, the 
increased prevalence of infectious disease in incarcerated populations can be attributed to 
structural determinants and social factors: racial and ethnic minorities and people with low 
income are often over-represented in prisons, and the criminalisation of drug use, sex work, 
and sexual minorities has resulted in high rates of incarceration among these groups. Mental 
illness also contributes to incarceration in many settings.2 Before incarceration, members of 
these marginalised populations tend to have little access to health-care resources, which 
results in sub-optimal health outcomes.3 During incarceration, few prisoners worldwide have 
consistent access to internationally recommended strategies4 to reduce the risk of 
transmission of HIV or other infectious diseases, including voluntary HIV testing, 
antiretroviral therapy (ART), sterile syringes, condoms, and opioid agonist therapies such as 
methadone or buprenorphine.5 Because of a culmination of these factors, HIV, hepatitis B 
virus (HBV), hepatitis C virus (HCV), and tuberculosis are particularly concentrated in 
prisons, and each independently and synergistically contributes to preventable morbidity and 
mortality in individuals and communities.1
In this paper, we review the clinical management of people with HIV, HBV, HCV, and 
tuberculosis in prisons. We focus on screening practices, treatment, and strategies applied to 
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link individuals to community-based treatment on their release. We identified 285 articles 
that were related to clinical care of HIV, viral hepatitis, or tuberculosis in prisons or after 
release, from 2013 to 2016 (figure). The scarcity of publications describing prison 
populations in low-income and middle-income countries highlights the need for more 
information about the overlap of HIV and other infections in these regions.
In this paper, HIV care is presented in the context of the HIV treatment criteria that classifies 
people with HIV as diagnosed, engaged in care, prescribed ART, or achieving viral 
suppression.6 This cascade has been used as a public health tool to prioritise areas for 
intervention with the goal of increasing the proportion of people with HIV achieving viral 
suppression.7 When viral suppression is achieved, HIV transmission is substantially 
decreased, both by individual and societal standards.8 The related strategy of using HIV 
treatment as prevention to control the epidemic outlines a multipronged approach to increase 
identification of people with HIV through testing, improving access to ART, and 
maintaining long-term treatment. Long-term treatment through retention in care is a priority 
for HIV care interventions,9 including for prison settings.10,11 This cascade is aligned with 
UNAIDS 90-90-90 targets by 2020, such that universal treatment of people with HIV would 
result in 73% of patients achieving viral suppression, which would translate to a 50% 
reduction in people with HIV by 2030.12 In addition, challenges, gaps in knowledge, and 
priorities for future research to improve the diagnosis and treatment of HIV, HBV, HCV, and 
tuberculosis among prisoners are highlighted in this review.
HIV in prisons
Incarcerated people have a disproportionate burden of HIV/AIDS as compared to their non-
incarcerated counterparts.13 Thus, initiatives within prison settings for HIV prevention, 
screening, treatment, and linkage to care after release have been developed; however, 
incarceration often disrupts HIV care for people who are engaged in HIV/AIDS treatment in 
the community.14
For people with HIV who are marginalised from care because of sub-optimally treated 
substance use disorders, psychiatric disorders, and other health disparities, incarceration 
could enable individuals to access HIV testing, ART, and general health care.15 These 
benefits, however, require that prisons have health infrastructures that can deliver 
comprehensive HIV services, including ART.14 High-income countries are better equipped 
for this purpose than are low-income and middle-income countries. Incarceration can also 
have negative consequences on HIV treatment. For people receiving ART in the community, 
arrest and detention often leads to an interruption of ART, which can be brief or long lasting 
depending on the availability of ART inside prison.16,17 Additionally, people detained in 
prisons might not acknowledge their HIV status, or might not take their medications in the 
presence of others because of a real or perceived stigma and discrimination, thus prolonging 
ART interruptions during detainment.18
Prisons should devise testing strategies that immediately link HIV positive patients to HIV 
care and ART within prison and ensure continuity of care after release to the community. 
Such strategies should respect basic human rights and preserve patient autonomy and 
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confidentiality. In 2009, WHO released guidelines recommending that confidential, 
voluntary HIV testing and counselling be available to all people detained in prison.19 These 
guidelines also emphasise that screening initiatives should be done ethically, ensuring 
individual autonomy and access to treatment for people testing positive. In the past 30 years, 
many prisons have incorporated HIV testing and screening, although not all have ensured 
that testing is voluntary and confidential. A 2008 review20 of HIV screening guidelines in 
Europe revealed that 61% of European Union countries have HIV testing standards that 
emphasise routine testing. In the USA, in 2008, 24 states tested all inmates at some point 
during custody.21 Adoption and implementation of HIV screening has led to higher 
identification of HIV while the immune system is preserved, and increased opportunity to 
provide appropriate treatment.22 Unfortunately, HIV testing is not always delivered in 
accordance with best practice guidelines within many prison settings; in many jurisdictions, 
mandatory HIV testing and segregation of people with HIV persists.23
The method of assessing HIV testing within prison settings can vary with respect to the 
ability of an individual to accept or decline testing. Presently, both mandatory and voluntary 
testing strategies exist. Mandatory testing requires that all inmates are tested for HIV 
without the ability to decline; conversely, voluntary testing preserves the ability of the 
individual to accept or decline an HIV test. Routine testing can include opt-out strategies, 
which dictate that HIV testing be done as part of routine medical care, unless the inmate 
declines or opts out of HIV testing. Testing can also be routinely offered, requiring the 
inmate to opt in. WHO, the European Centre for Disease Prevention and Control (ECDC), 
and the US Centers for Disease Control and Prevention (CDC) all oppose mandatory HIV 
testing, stating that it is unethical.24 Testing should be available when requested by the 
individual and to all people passing through a prison setting. Routine opt-out HIV testing 
should allow autonomy in decision making, ensuring that inmates are explicitly and 
suffciently informed and able to decline testing if desired. Routine opt-out testing strategies 
have historically resulted in the highest proportion of people completing voluntary testing25 
and should be implemented when feasible. Furthermore, the way in which opt-out testing is 
done should be adjusted to maximise testing rates and linkage to care, while preserving 
informed decision making.
Incarcerated individuals with HIV should be assessed by trained HIV clinicians and offered 
ART, regardless of whether they are in facilities designed for prison sentences of short or 
long duration . Nonetheless, ART is only available in prisons in less than a third of countries 
worldwide.26 Where ART is available, HIV-related mortality in prisons is similar to that of 
the non-incarcerated community, which supports the need for appropriate diagnosis and 
treatment.27 In the USA, the rate of AIDS-related deaths in state prisons dropped to less than 
the rate for the US general population in 2009, suggesting that imprisoned individuals with 
unrestricted access to ART can have substantial improvements in their HIV disease status.28 
Additionally, most prisons and jails in the USA provide ART; however, 16–34% of 
incarcerated people with HIV do not report taking any prescription medication during 
incarceration.29 Organisational and institutional barriers, such as a scarcity of specialised 
care, unavailability of specific ART regimens, and unwillingness to disclose HIV status to 
prison guards, medical staff, or other inmates can affect HIV treatment inside prisons. Best 
practices for the clinical care of HIV in prisons should be consistent with national and 
Rich et al. Page 4
Lancet. Author manuscript; available in PMC 2017 July 11.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
international guidelines and should include assessment by an HIV specialist; screening for 
sexually transmitted infections, HBV, HCV, and tuberculosis; and immediate prescription of 
ART, routine monitoring of HIV treatment, and discharge planning that includes linkage to 
care and support services to facilitate successful treatment after release.30 Furthermore, 
addressing co-occurring social and medical comorbidities such as homelessness, 
unemployment, mental illness, substance use disorders, and trauma are crucial to ensure 
successful outcomes.
The health benefits from provision of ART during incarceration are often lost following 
release from prisons, especially for women.31 Although high levels of viral suppression are 
achieved by many patients during incarceration, community re-entry is associated with loss 
of viral suppression. Many factors contribute to this loss of viral control after release, 
including relapse to substance use, unstable housing and unemployment, failure to access 
ART in the community because of loss of health entitlements, and reduced access to health 
care.32–34 Similarly, the immediate period after release has been associated with poorer HIV 
treatment outcomes (such as increased viral load and decreased CD4 cell count),35 high risks 
of HIV-related mortality, and drug overdose.36 These worsened outcomes among patients 
with HIV are especially true among those with comorbid alcohol and other substance use 
disorders.37 Reviews of HIV and incarceration found that there is less viral suppression after 
release than before incarceration38 and failure to maintain viral suppression leads to 
increased HIV transmission in the community.39 Therefore, addressing the needs of people 
with HIV during and following incarceration is imperative and is an essential component of 
a broader, more comprehensive strategic plan. Indeed, mathematical modelling from 
Ukraine documents40 show that HIV risk taking among prisoners who inject drugs and who 
subsequently transition to the community from prison contribute most to HIV transmission 
in the population. Scaling up opioid agonist treatments in prison and retaining patients on 
this regimen post-release would be the most effective strategy to reduce new infections in 
people who inject drugs. These needs are increasing given the continued scale-up of efforts 
to prevent HIV through treatment in many communities. There is evidence that HIV 
prevention strategies can be compromised by incarceration, especially among people who 
use drugs and have HIV infections.
Despite evidence of increased rates of HIV-related complications after release from prison, 
many studies have identified effective mechanisms for health maintenance, including case 
management,41 discharge planning,10 transitional care coordination,42 and focusing on 
combined medical and social needs.43 Findings from a single randomised trial did not find a 
benefit in the use of case management for released prisoners with HIV; however, these 
findings may be unique to the particular setting.44 Numerous studies have explored the use 
of interventions to lower the possibility of interrupted HIV care and ART posed by transfer 
between prison and community settings. The role of transfers between facilities during 
incarceration has an unknown effect on care provision, and is under-examined. International 
recommendations for transitioning prisoners include directly administered ART and opioid 
agonist therapies for people with HIV and opioid disorders;45 others have suggested that 
case management, coordinated discharge planning, and peer navigation might also be 
useful.46 Opioid agonist therapies that are initiated before release and continued into the 
community have been associated with higher proportions of viral suppression in people with 
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HIV; moreover, randomised trials47 of treatment for alcohol and opioid use disorders with 
extended-release naltrexone are promising and are ongoing (ClinicalTrials.gov, 
NCT01077310 and NCT01246401).
The criminalisation of illicit drugs has resulted in a substantial proportion of prisoners in 
many jurisdictions serving sentences for non-violent drug use. As such, the role of 
incarceration in the HIV/AIDS pandemic among people who inject drugs deserves special 
mention. For example, in Vancouver, Canada, epidemiological estimates suggested that one 
in five HIV infections during an explosive outbreak of HIV/AIDS in the 1990s were 
associated with incarceration.48 To combat HIV infection associated with incarceration, 
several evidence-based interventions tailored specifically for those with criminal justice 
experience who are at risk for HIV have been developed, but these programmes are only 
available after release and are unavailable in most prisons.49 Prisons should, therefore, 
consider implementing harm reduction strategies alongside existing prevention programmes 
to reduce HIV transmission in at-risk prisoners.
HIV transmission within prison settings can occur, but transmission rates vary and are 
poorly quantified, ranging from zero incidence to well documented outbreaks. HIV 
transmission within prison is discussed in more detail in accompanying articles in this 
series.40,50 Ensuring that all people with HIV who are incarcerated are prescribed ART is a 
key strategy to reduce HIV transmission within prison.
Viral hepatitis in prisons
People who are incarcerated are 9–13 times more likely to be HCV-infected than non-
incarcerated members of the community.51 Left untreated, chronic HCV infection leads to 
cirrhosis and hepatocellular carcinoma and is a leading cause of liver transplantation in high-
income countries.52 The staggering rates of HCV infection in prisoners and the substantial 
risks associated with untreated HCV disease underscore the need for HCV screening and 
access to HCV treatment in prisons.
WHO recommends that “all prisoners should be tested for hepatitis C”.53 In the USA, risk-
based screening is recommended by the CDC and the Federal Bureau of Prisons, meaning 
that prisoners should be tested only if there are known risk factors, including those with a 
history of injection drug use (panel 1). People with HIV and those with liver disease should 
also be tested for HCV. The CDC added one-time HCV testing for all Americans born 
between 1945 and 1965, as there was an increased prevalence of HCV in this birth cohort, in 
addition to the risk-based testing recommendations in an effort to diagnose more people with 
HCV. Some have argued, however, that routine HCV testing for all prisoners is warranted 
given the high prevalence of disease.54 Prison offcials might be reluctant to expand HCV 
testing given the potential costs associated with treatment, and this reluctance has led to vast 
underdiagnosis of the disease. Some prisons in high-income countries are expanding HCV 
treatment, but uptake remains slow. Internationally, adherence to WHO guidelines for HCV 
screening in prison settings is inadequate. For instance, in western Europe, only ten (34%) of 
29 surveyed countries reported HCV screening programmes for prisoners.24 Where HCV 
screening is available in prison settings, universal screening methods are recommended55 but 
Rich et al. Page 6
Lancet. Author manuscript; available in PMC 2017 July 11.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
are seldom used. There are indications that risk-based screening results in substantial gaps in 
patient identification.54,56 Universal, opt-out screening for HCV in prison settings is 
essential to reduce HCV transmission and HCV-associated morbidity and mortality.57
HCV treatment developments have provided therapies that, for the first time, are highly 
effective (ie, >90% cure rates), tolerable, simple (one pill per day), and of short duration (12 
weeks for most patients).58 These medications, however, are very expensive, and treatment 
for chronic HCV has remained underused in prisons.58,59 In countries where HCV treatment 
is available to prisoners, treatment remains restricted to individuals who are classified as 
high-priority candidates for treatment, such as those with cirrhosis.60 This clinical practice
—which withholds effective treatment from most incarcerated individuals with chronic HCV 
infection—could be characterised as a human rights violation.61 Additionally, failure to 
engage chronically infected prisoners in effective treatment is likely to contribute to viral 
transmission patterns within groups in prison and community settings. In the near future, the 
availability of HCV treatment to inmates will probably become an area of increased 
litigation, policy discussion, and ethical consideration.
Cost frequently restricts HCV treatment, but several studies57,60,62 have documented that 
early HCV detection and treatment is cost-effective, including for individuals who are 
incarcerated. Although early-stage treatment of all individuals with chronic HCV infection 
produces immediate costs, the reduced rates of HCV transmission and liver-related 
morbidity and mortality reduce costs in the long term.58,63 Indeed, widespread HCV 
treatment of incarcerated populations (treatment-as-prevention) would help bring about the 
global elimination of HCV.63 The prevalence of HCV among prisoners is elevated in many 
countries of eastern Europe and central Asia compared with other regions,64-66 exceeding 
60% prevalence in Ukraine,64 where incarceration rates are among the highest in the world 
and is comprosed of many people who inject drugs.40 Nonetheless, some countries in the 
region are making progress. Efforts in Georgia are underway to eliminate HCV, including 
treatment of prisoners.67
As global elimination of HCV through treatment becomes viable, applying lessons learned 
from increasing access to ART for HIV infections in low-income and middle-income 
countries could prove to be essential in reducing the burden of HCV globally.68 Mechanisms 
that have been used to increase the affordability of ART, including generic competition, 
voluntary licensing, tiered pricing, and the Medicines Patent Pool should be applied to 
reduce high prices of HCV treatment and improve access to care in low-income and middle-
income countries.68 The establishment of intergovernmental agencies and foundations for 
HCV that are similar to those for HIV (eg, the Global Fund to Fight AIDS, Malaria, and 
Tuberculosis), which aid in the purchase of diagnostic kits and medications, might also be 
essential in reducing the burden of HCV in low-income and middle-income countries.68 For 
maximal effect, future efforts to treat people with HCV should include individuals who are 
incarcerated. Because of the scarcity of published data, clinical care for HBV infections is 
explored in panel 2.
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Tuberculosis in prisons
The burden of tuberculosis in prison settings remains a substantial public health problem, 
especially in low-income and middle-income countries.1 Tuberculosis thrives in 
disadvantaged, impoverished populations including among people in prisons, particularly 
those that are overcrowded and poorly ventilated. The increased prevalence of tuberculosis 
in prisons can be partly attributed to the emergence of drug-resistant tuberculosis forms, 
such as multi-drug resistant and extensively-drug resistant tuberculosis.75 In response to 
these ongoing challenges, WHO released a global strategy in 201376 with the goal of ending 
the tuberculosis epidemic by 2035; this strategy includes the expansion of preventive 
treatment of latent tuberculosis infection for individuals in congregate settings, including 
prisons.
Tuberculosis screening algorithms, screening procedures, and diagnostic practices differ 
across the globe. WHO published cost-effective screening algorithms in 2012;77 however, 
these recommendations are more likely to be adopted by high-income countries that are not 
as restricted by costs for GeneXpert MTB/RIF (Xpert) and light-emitting diode (LED) 
fluorescence microscopy, which are the gold-standard in diagnostics.78,79 Nonetheless, it is 
low-income and middle-income countries that are most profoundly impacted by 
tuberculosis, especially in prisons, thereby making such settings high priority for 
tuberculosis elimination efforts. Results from a systematic review79 suggest that in countries 
of all income levels, symptom questionnaires are the most common screening methods in 
prison settings, but findings from Malaysia and Brazil suggest that such strategies are 
insuffcient.23,80 In low-income and middle-income countries, the most common screening 
procedures outside prison are the presence of cough and chest radiography; in high-income 
countries the most common screening procedures are chest radiography, tuberculin skin 
tests, and the observation of at least one tuberculosis symptom.79 Diagnostic practices also 
vary across income areas. In low-income and middle-income countries, the most common 
diagnostic practices include sputum smear microscopy and solid culture; but high-income 
countries also include chest radiography and tuberculin screen tests.79 Interferon-gamma 
release assays can also play a role in tuberculosis screening in high-income countries.81 A 
study of screening for tuberculosis by use of several strategies found sputum smear 
microscopy to be completely ineffective at identifying tuberculosis in prisoners, and Xpert 
identified only 58% of cases.82
The deffciency of adequate diagnostic tools for tuberculosis in prison settings is a particular 
challenge in low-income and middle-income countries.79 Diagnostic services are often 
provided by external laboratories, which can lead to delays in diagnosis.83 Bacteriological 
services that are run in-house, such as sputum smear microscopy, often lack quality control; 
the diagnostic microscopes in prisons are often poorly maintained, and staff might have 
insuffcient training in the use of these diagnostic tools.84,85 In low-income and middle-
income countries, improved laboratory services and biosafety measures are crucial to 
increase detection and treatment of tuberculosis in prisons.
Internationally, data on the clinical management of active and latent tuberculosis infections 
in prison settings are scarce. A systematic review86 suggests that in countries of all income 
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levels, initiation and completion rates of isoniazid preventive treatment for individuals with 
latent tuberculosis infection remain low, particularly in short-term detention facilities. In all 
settings, regardless of income level, the clinical management of active and latent 
tuberculosis infections in prisons can be complicated by challenges in implementing 
supervised treatment and the inability of some prisoners to pay for tuberculosis 
treatment.87,88 In countries at all income levels, the uncontrolled sub-optimal quality of 
tuberculosis medications pose substantial challenges to tuberculosis control.87,88 Even in 
high-income countries, tuberculosis treatment completion rates following release from 
prison remain relatively low, which is likely to be caused by multiple logistical and other 
challenges to remaining in care.89 Internationally, there is little literature on linkage to care 
for tuberculosis treatment after release; nonetheless, WHO has prioritised ensuring treatment 
completion after incarceration for those who are released during treatment.90 Substantial 
challenges in the clinical management of tuberculosis in prison settings exist in all income 
areas, and a greater allocation of resources to tuberculosis management is likely to be 
needed to control the infection in prison settings.
Several factors contribute to tuberculosis transmission in prisons that impede tuberculosis 
control, including overcrowding, insuffcient ventilation, extended confinement inside cells, 
generally poorer health, co-infections that exacerbate tuberculosis infection such as HIV, 
delayed case detection, inadequate treatment of infected patients, high inmate turnover, and 
poor implementation of tuberculosis infection control measures.79,83,91 Both legislation and 
international guidelines that address these key areas should be implemented to curb 
transmission and facilitate tuberculosis control in prisons.
Management of co-occurring disorders
In addition to the amplification of various infectious diseases in prisoners, overlapping 
psychiatric and substance use disorders are common comorbid conditions, and in the 
absence of effective screening and treatment in prisons, undermine effective treatment.92 
Both psychiatric and substance use disorders are independent correlates of HIV infection, 
and sub-optimal treatment of these conditions for people with HIV is associated with 
underdiagnosis and poor continuity of HIV care after release (panel 3). Many of these 
conditions can be effectively treated with pharmacotherapies, especially opioid and alcohol 
use disorders and schizophrenia-spectrum disorders. The fifth Edition of the Diagnostic and 
Statistical Manual now, for the first time, supports treatment for those in “controlled 
environments” like prisons and jails, even when there is no evidence of ongoing physical or 
psychological dependence.96 Randomised trials97 support implementing methadone 
according to patient need during incarceration and continuing treatment after release from 
prison.
Implications for public health of non-incarcerated communities
Comorbidity of infectious diseases (eg, HIV, hepatitis B, hepatitis C, or tuberculosis), mental 
illness, and addiction is common among individuals who are incarcerated, and these 
comorbidities complicate the delivery of care both during incarceration and after release.1 
Given the complexity of treatment required during and after incarceration, there is a need for 
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innovation in medical care provision. Prisoners often do not have access to specialists for 
treatment and those with HIV in particular have poor access to specialty care. Access to care 
in many places could be diminished because prisoners are required to pay for medical 
treatment during incarceration, often shifting the financial burden of treatment and 
medications onto family members.
In many countries, prisons and jails house low-income individuals with many syndemic 
comorbidities, many of whom do not have access to medical care and social services in the 
community. In view of this, prisons are important sites to develop and implement public 
health interventions. The 2012 Geneva Declaration on health-care in prisons provides 
guidelines based on humanitarian law and is guided by seven principles: having access to a 
physician, equivalence of care with the community, maintaining patient consent and 
confidentiality, providing adequately scaled preventive services, offering humanitarian 
assistance, professional independence (minimising dual loyalty), and professional 
competence.98 The declaration calls for these principles to be integrated into medical 
provision across the globe. Prisons should be integral sites of collaboration for screen, test, 
treat, and retain strategies to reduce community transmission of infectious diseases both in 
prison and after release. However, other innovative and practical strategies are also 
necessary. WHO recommends that medical care for prisoners be handled by the same 
governmental organisation that oversees general health-care provision (eg, the Ministry of 
Health) rather than the Ministry of Justice or Ministry of the Interior or a separate and 
unique entity only tasked with prison health, to improve accordance with the legal guarantee 
of equivalent health care for prison and community populations.99 Oversight of prisoner 
health care by the Ministry of Health would be able to ensure quality of care in prison that 
was consistent with the care provided in the community and would enable the improved 
provision of continued care after release from prison.
Under international law, prisoners retain their human rights and fundamental freedoms, 
except for such restrictions on their rights required by the fact of incarceration (panel 4).100 
States therefore have an obligation to provide medical care to prisoners at least equivalent to 
that available outside of prisons. The 164 countries that are party to the International 
Covenant on Economic, Social and Cultural Rights should guarantee minimum core 
obligations with respect to the right to health, including the provision of essential primary 
care and medicines.3 States should also pledge non-discriminatory access to health care and 
the equitable distribution of health facilities and services.105 Infectious disease control is 
also crucial to protect both prisoners and staff, and to prevent disease outbreaks; a summary 
of HIV, viral hepatitis, and tuberculosis prevention strategies for prison settings is provided 
in panel 5.
In addition to immediate reforms aimed at bringing prison health-care into line with the 
recommendations of the Geneva Declaration, the implementation of innovative strategies to 
address the challenges inherent in health-care delivery for incarcerated individuals could 
improve health outcomes. For example, in the USA, the Extension for Community 
Healthcare Outcomes Project links primary care doctors in prisons with specialty care 
experts at an academic hub, helping to alleviate the problems caused by a shortage of 
specialty care physicians in prisons and jails.106,107 Unfortunately, the principle of 
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equivalence of medical care between prison and community settings is too often negated in 
practice. Furthermore, in many settings the clinical care and health of individuals in 
susceptible and marginalised groups, such as members of sexual and racial minorities or 
people who use illicit drugs, would be best served by structural reforms to curb the 
prevalence of incarceration.
Finally, coordinated general and behavioural health care, or integrative care, is necessary for 
all prisoners. WHO, UNAIDS, CDC and the International Association of Providers of AIDS 
Care recommend integrative care for people with HIV. However, the organisational structure 
of most prison health settings is not set up to abide by these recommendations, especially in 
low-to-middle-income countries that might not have funding available for community 
primary care provision. Additionally, clinical staff and social workers should acknowledge 
the social determinants of health that are also negatively affected by incarceration. 
Therefore, any treatment initiatives need to recognise the role that social factors play in the 
health disparities faced by current or former prisoners.
Conclusion
In providing clinical care to incarcerated people with HIV, viral hepatitis, tuberculosis or a 
combination of infections, prisons should provide confidential screening and treatment, 
education, linkage to care after release, and address multiple co-occurring issues both during 
incarceration and once released into the community. Further research on the provision of 
health care in prisons is needed in all areas of the world—in countries at all income levels. 
Alternatives to incarceration that preserve public safety and lead to improved health and 
public health outcomes should be rigorously pursued.
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Search strategy and selection criteria
We searched reports related to HIV, hepatitis B virus, hepatitis C virus, and tuberculosis 
clinical care in adult prison settings. Keywords and MeSH headings related to 
incarceration (ie, “inmate”, “prisoner”, “felon”, “jail”) were paired with search terms 
pertaining to each infectious disease of interest. We limited our search to PubMed articles 
that were published in English between Jan 1, 2013, and March 29, 2015, focusing on 
systematic reviews and meta-analyses when available. We also reviewed and included 
key articles that were published before 2013. We retrieved and reviewed over 1122 
unique citations, of which 285 were selected for inclusion of this analysis. Most (118 
articles, 41%) were focused on populations in the USA, followed by Brazil (18 articles), 
Australia (14), Iran (13), the UK (ten), and Spain (nine). Further information on our 
search strategy, inclusion criteria and a bibliography of all included articles are available 
in the appendix. Nearly a quarter of the global prison population is held in prisons and 
jails in the USA, and as a result, much of the literature related to infectious diseases in 
prison settings is from this region. Moreover, there are fewer resources for research and 
for treatment in low-income and middle-income countries. Wherever data are available, 
we discuss and present research from around the world to provide a more balanced, 
international perspective.
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Key messages
• Individuals in prison are disproportionately affected by HIV, hepatitis B and 
C, and tuberculosis compared with the rest of the global community yet often 
have less access to testing methods and treatments, to care for these 
infections.
• Structural barriers, stigma, and insuffcient resources impede the delivery of 
optimal clinical care for these diseases in prison settings.
• Criminal justice reforms and increased collaboration between prison and 
public health offcials could lead to substantial positive effect on the health of 
affected populations in addition to contributing to a general decline in 
transmission of these infectious diseases in community settings.
• Monitoring and accountability of human rights abuses and the availability of 
treatment for HIV, viral hepatitis, and tuberculosis treatment in prison settings 
is important to ensure respect for human rights, autonomy, confidentiality, and 
to maximise public health of the greater public.
• The interrelated, negative correlation (ie, syndemic) of incarceration, 
substance use disorders, mental illness, and infectious disease with disease 
outcome complicate the optimal delivery of medical care in prison settings 
and should be addressed.
• For prison-based health care to reach the same standards as those provided in 
the community, financial support in the range of tens of billions of dollars will 
be needed (appendix), along with support from medical and humanitarian 
organisations across the globe. This is particularly true in low-income and 
middle-income countries.
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Panel 1: Patient vignette 1
In the early 1980s, a 24-year-old African American man was incarcerated for the first 
time for possession of crack cocaine in the USA. During the next 6 years, he was caught 
in the cycle of arrest for drug-related charges, incarceration, and release back to the 
community. In 1990, the local Department of Corrections instituted a routine HIV testing 
programme that provided voluntary HIV testing as part of the intake medical examination 
to the jail. He tested positive for HIV for the first time that year. Over the next decade, he 
continued to use and sell crack cocaine, continued to cycle in and out of jail, and served 
several prison sentences.
When incarcerated, he was assessed by HIV care providers and prescribed antiretroviral 
therapy (ART), which he took consistently. However, every time he was released, these 
gains were quickly lost as his environment pulled him back into drug use and dealing. 
HIV treatment and seeing his HIV care provider in the community were not priorities, 
replaced by the everyday battle to survive in his disenfranchised, low-income urban 
environment.
As part of his care within the prison, he tested positive for hepatitis C virus in 1998. He 
was enrolled in a case management programme that attempted to stabilise his life during 
transitions between prison and the community. Despite these attempts, the cycle of 
reoffending continued until 2006 when he was offered early parole from the prison if he 
entered a community-based residential drug rehabilitation programme. With the support 
of the prison-based case management programme, he entered and completed drug 
treatment and subsequently gained temporary employment. He had one relapse with 
crack cocaine the following year but was able to enter a community-based drug treatment 
programme that eventually hired him as a maintenance worker.
Since 2007, he has been steadily employed by this community-based organisation and he 
has maintained his recovery from crack cocaine use. His HIV infection is well controlled 
by ART. In 2010, he was given treatment for his chronic hepatitis C virus infection but 
was unable to tolerate interferon-based treatment. In 2013, he was diagnosed with 
hepatocellular carcinoma that was treated by radiofrequency ablation. His hepatitis C 
virus infection was cured in 2014 with an antiviral regimen including a new direct-acting 
antiviral agent. A recurrence of his hepatocellular carcinoma was detected in 2015.
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Key points
• Hepatitis C virus infection leads to substantial morbidity and mortality in 
HIV-infected prisoners.
• Prison settings are an important venue for HIV testing to reach people who 
use drugs.
• Treatment of HIV inside of prison settings can be successful.
• Community re-entry can destabilise HIVtreatment.
• Interventions based on prison-community partnerships can help to mitigate 
the risks associated with community re-entry.
• Employment, housing, health insurance, and other social services can be 
fundamental stabilising factors for people re-entering the community.
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Panel 2: Hepatitis B prevention in prison settings
People who are incarcerated have a disproportionate burden of hepatitis B virus (HBV) 
infection.1 Although global HBV immunisation coverage in infants increased from 8% to 
82% from 1994 to 2014,69 chronic HBV infection remains high in prison settings, 
especially in low-income and middle-income countries where HBV vaccine uptake has 
been lower.70 Prisoners are highly susceptible to HBV because of the low prevalence of 
vaccine-induced immunity. Data on HBV susceptibility in prison settings are rare, but 
one study done in New South Wales, Australia, found that more than half of people 
admitted to prison were susceptible to HBV, and prison entrants were more susceptible to 
several other vaccine-preventable diseases than members of the surrounding 
communities.71
To reduce HBV susceptibility in prison settings, some countries have implemented 
prison-based HBV vaccination programmes. Routine HBV vaccination programmes 
implemented in prisons in Scotland, England, and Wales have been particularly 
successful in achieving vaccine coverage and uptake.72,73 Results from one study74 in the 
USA suggest that a combined hepatitis A and B vaccination programme, with an 
accelerated schedule among high-risk inmates, can be successfully implemented in a jail 
setting. These initiatives play an essential role in preventing chronic disease among 
members of a susceptible population.
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Panel 3: Patient vignette 2
In the mid-2000s, a 16-year-old white American woman was sentenced to a juvenile 
detention facility for aggravated assault. These charges stemmed from an altercation with 
her foster mother. In the years before her arrest, she had cycled through countless foster 
families—some of whom were physically and sexually abusive. During her stay in the 
juvenile detention facility, she was diagnosed with a generalised anxiety disorder and 
post-traumatic stress disorder, and after her release she was prescribed a 2-week supply 
of antidepressants and was referred to a local therapist. Because of the chaos of the post-
release environment and insuffcient support from her foster family, she was unable to 
follow up with therapy.
In her early twenties, she began misusing prescription opioid medications, which later led 
to heroin use. Her boyfriend at the time encouraged her to engage in sex work to 
financially support their mutual opioid addiction. At 23 years of age, she was sentenced 
to an adult prison for charges related to prostitution. Early in her 18-month sentence, she 
learned that she was HIV positive.
During her stay in prison, she resumed taking antidepressants and initiated antiretroviral 
therapy. She was also linked with case managers who assessed her medical and social 
support needs and began to plan for a successful transition into the community after 
release. She was linked to community HIV and mental health services and many other 
public assistance programmes. Since her release, she has maintained consistent 
employment as a cashier and is in recovery from opioid dependence. Her HIV is well 
controlled on antiretroviral therapy, and symptoms of her generalised anxiety disorder 
and post-traumatic stress disorder are well managed.
This patient still has many struggles but partly attributes her success after release to the 
comprehensive discharge planning that enabled her to have continuous HIV-related 
medical care and her access to employment opportunities provided by a community-
based organisation that helps formerly incarcerated women find jobs.
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Key points
• While we present a single case here, generally, women who are sex workers 
and have a history of incarceration have an increased likelihood of becoming 
HIV positive93, and the number of women incarcerated around the world 
continues to increase.9395
• An abundance of research and individual testimony has provided evidence 
that providing people with support both before and after release increases 
successful re-entry and HIV-related outcomes long term.
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Panel 4: Seeking access to HIV treatment in prisons through the courts
In the past two decades, individuals inside and outside prison have sought access to 
health care, especially HIV treatment, through appeals to courts and claims of human 
rights. Plaintiffs frequently put forward claims related to right to health care, life, and 
non-discrimination. One early case, Van Biljon and Others. v. Minister of Correctional 
Services (1997)101, which was heard in South Africa, addressed the question of whether 
the state had an obligation to provide ART to prisoners with HIV infection even though 
access to ART was also unavailable to non-prisoners in public health facilities in the 
country. The court did not rule on the issue of when prisoners should be eligible to 
receive treatment, but it did rule in favour of the prisoners that treatment should be 
provided at the expense of government and that prisoners on antiretroviral therapy at the 
time of incarceration have a right to continued treatment.101 The Court further found that 
the state has greater obligations to prisoners than to those outside prisons, as “[u]nlike 
persons who are free, prisoners have no access to other resources to assist them in 
gaining access to medical treatment”. It further noted that prisoners with HIV were 
unique because the Government is “keeping these prisoners in conditions where they are 
more vulnerable to opportunistic infections than HIV patients outside”.101
A more recent case, Tapela and Others. v. Attorney General (2014), challenged the policy 
of the government of Botswana that provided prisoners free antiretroviral treatment only 
if they were citizens of Botswana.102 In their ruling in this case, the Botswana High 
Court held that the policy of denying antiretroviral treatment to non-citizen prisoners was 
a violation of the Constitution of Botswana, including the right to life and to non-
discrimination. The court found that the denial of antiretroviral treatment increased not 
only the risk of “premature death” but also HIV and tuberculosis transmission to other 
inmates. The court noted that although the prisoners' liberty had been curtailed, their 
other rights remained intact, and that it was impermissible for the State to “extend the 
limits of punishment by withholding certain services to which inmates are lawfully 
entitled”.102
Courts have also ruled in favour of prisoners seeking access to treatment for chronic 
hepatitis C infection (eg, Testa v Croatia, 2007)103 and treatment for tuberculosis 
(Staykov v Bulgaria, 2006)104.
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Panel 5: Summary of HIV, viral hepatitis, and tuberculosis prevention 
strategies for prisons
HIV and hepatitis C
• Treatment-as-prevention strategies should be used to increase the 
identification of people with HIV through testing, improving treatment 
access, and engagement in care
• Opioid agonist therapies initiated before release and continued into the 
community have been associated with reduced engagement in risky behaviour
• Sterile needle distribution and condom distribution in prisons can reduce HIV 
and hepatitis C virus incidence
Tuberculosis
• Screening at intake and treatment fortuberculosis and latent tuberculosis 
infection is crucial to reduce incidence in prisons
• Prison administrators should ensure that facilities do not exceed maximum 
capacity and are suffciently ventilated to prevent tuberculosis transmission
Hepatitis B
• Screening and treatment for hepatitis B virus is essential to reduce 
transmission in prisons
• Routine hepatitis B virus vaccination programmes have been successful in 
achieving vaccine coverage and uptake
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Figure. Global distribution of publications related to the clinical care and post-release outcomes 
of incarcerated people with HIV, viral hepatitis, or tuberculosis published 2013–16
Distribution of the citations acquired as a result of the search strategy used in the systematic 
review. Search strategy and sources listed in the appendix.
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